TY - JOUR
T1 - Combining Mg–Zn–Ca Bulk Metallic Glass with a Mesoporous Silica Nanocomposite for Bone Tissue Engineering
AU - Chu, Yun Shin
AU - Wong, Pei Chun
AU - Jang, Jason Shian Ching
AU - Chen, Chih Hwa
AU - Wu, Si Han
N1 - Funding Information:
Funding: This study was supported by research grants from the National Health Research Institutes (NHRI‐EX111‐10911EC) and the Ministry of Science and Technology of Taiwan (MOST110‐2113‐M‐ 038‐004).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/5
Y1 - 2022/5
N2 - Mg–Zn–Ca bulk metallic glass (BMG) is a promising orthopedic fixation implant because of its biodegradable and biocompatible properties. Structural supporting bone implants with osteoinduction properties for effective bone regeneration have been highly desired in recent years. Osteogenic growth peptide (OGP) can increase the proliferation and differentiation of mesenchymal stem cells and enhance the mineralization of osteoblast cells. However, the short half‐life and nonspecificity to target areas limit applications of OGP. Mesoporous silica nanoparticles (MSNs) as nanocarriers possess excellent properties, such as easy surface modification, superior targeting efficiency, and high loading capacity of drugs or proteins. Accordingly, we propose a system of combining the OGP‐containing MSNs with Mg–Zn–Ca BMG materials to promote bone regeneration. In this work, we conjugated cysteine‐containing OGP (cgOGP, 16 a.a.) to interior walls of channels in MSNs and maintained the dispersity of MSNs via PEGylation. An in vitro study showed that metal ions released from Mg–Zn–Ca BMG promoted cell proliferation and migration and elevated alkaline phosphatase (ALP) activity and mineralization. On treating cells with both BMG ion‐containing Minimum Essential Medium Eagle‐alpha modification (α‐MEM) and OGP‐conjugated MSNs, enhanced focal adhesion turnover and promoted differentiation were observed. Hematological analyses showed the biocompatible nature of this BMG/nanocomposite system. In addition, in vivo micro‐computed tomographic and histological observations revealed that our system stimulated osteogenesis and new bone formation around the implant site.
AB - Mg–Zn–Ca bulk metallic glass (BMG) is a promising orthopedic fixation implant because of its biodegradable and biocompatible properties. Structural supporting bone implants with osteoinduction properties for effective bone regeneration have been highly desired in recent years. Osteogenic growth peptide (OGP) can increase the proliferation and differentiation of mesenchymal stem cells and enhance the mineralization of osteoblast cells. However, the short half‐life and nonspecificity to target areas limit applications of OGP. Mesoporous silica nanoparticles (MSNs) as nanocarriers possess excellent properties, such as easy surface modification, superior targeting efficiency, and high loading capacity of drugs or proteins. Accordingly, we propose a system of combining the OGP‐containing MSNs with Mg–Zn–Ca BMG materials to promote bone regeneration. In this work, we conjugated cysteine‐containing OGP (cgOGP, 16 a.a.) to interior walls of channels in MSNs and maintained the dispersity of MSNs via PEGylation. An in vitro study showed that metal ions released from Mg–Zn–Ca BMG promoted cell proliferation and migration and elevated alkaline phosphatase (ALP) activity and mineralization. On treating cells with both BMG ion‐containing Minimum Essential Medium Eagle‐alpha modification (α‐MEM) and OGP‐conjugated MSNs, enhanced focal adhesion turnover and promoted differentiation were observed. Hematological analyses showed the biocompatible nature of this BMG/nanocomposite system. In addition, in vivo micro‐computed tomographic and histological observations revealed that our system stimulated osteogenesis and new bone formation around the implant site.
KW - bone tissue engineering
KW - mesoporous silica nanoparticles
KW - Mg–Zn–Ca bulk metallic glass
KW - osseointegration
KW - osteoconduction
KW - osteogenic differentiation
KW - osteogenic growth peptide
KW - osteoinduction
UR - http://www.scopus.com/inward/record.url?scp=85130742836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130742836&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics14051078
DO - 10.3390/pharmaceutics14051078
M3 - Article
AN - SCOPUS:85130742836
SN - 1999-4923
VL - 14
JO - Pharmaceutics
JF - Pharmaceutics
IS - 5
M1 - 1078
ER -